Perimenopause and the Endocannabinoid System: What the Research Is Beginning to Show

Perimenopause is one of the most physiologically complex transitions in human biology, and one of the most poorly understood from a patient's perspective. The window of hormonal fluctuation that precedes menopause — typically spanning four to ten years, most often beginning in the mid-forties — is characterised not by a steady hormonal decline but by an erratic pattern of estrogen and progesterone fluctuation in which individual months or cycles can be dramatically different from each other. Hot flashes, disrupted sleep, mood instability, cognitive changes, anxiety, and joint discomfort are among the most reported symptoms — and their unpredictability is often as difficult to manage as their presence. The endocannabinoid system sits at the intersection of most of these symptom domains, and its relationship to the hormonal changes driving them is more specifically documented than is generally understood.

Estrogen and the ECS — A Bidirectional Relationship

The relationship between estrogen and the endocannabinoid system is bidirectional and well-documented in preclinical research. Estrogen upregulates the expression of CB1 receptors in limbic regions — particularly the hippocampus, amygdala, and prefrontal cortex — and increases anandamide availability by suppressing FAAH activity. When estrogen levels are adequate, the limbic ECS is more responsive: stress responses are terminated more efficiently, anxiety tone is modulated more effectively, and sleep architecture is better supported.

The perimenopausal transition disrupts this relationship through the erratic estrogen fluctuation that characterises the phase. During periods of estrogen decline, FAAH activity increases — the enzyme that degrades anandamide becomes more active, reducing anandamide availability. CB1 receptor expression in limbic tissue decreases. The ECS loses the upregulatory support that adequate estrogen provided. This is not a gradual, linear decline — it mirrors the erratic hormonal fluctuation of perimenopause itself, meaning ECS tone can vary significantly from week to week as estrogen levels fluctuate.

This estrogen-ECS relationship was characterised primarily through animal models, initially by Bradshaw and colleagues (2006) and subsequently confirmed and extended by multiple research groups. The human data confirming the same bidirectional relationship is more limited but consistent in direction: observational studies have found lower endocannabinoid levels in postmenopausal women compared to premenopausal women, and the hormonal fluctuation of perimenopause is associated with variable ECS tone that tracks, at least directionally, with estrogen fluctuation.

How ECS Disruption Maps to Perimenopausal Symptoms

The symptom domains most associated with perimenopause map closely onto the regulatory functions of the ECS — which is not coincidental given the documented estrogen-ECS relationship.

Vasomotor symptoms — hot flashes and night sweats — involve thermoregulatory dysregulation in the hypothalamus. CB1 receptors are expressed in hypothalamic thermoregulatory circuits, and endocannabinoid signalling is involved in the modulation of those circuits. Preclinical work has found that ECS disruption in hypothalamic tissue produces thermoregulatory instability that parallels vasomotor symptoms. Whether this mechanism contributes to hot flash frequency and severity in perimenopausal women is an active research area; the mechanistic plausibility is established, the clinical evidence is preliminary.

Sleep disruption — among the most commonly reported and most debilitating perimenopausal symptoms — involves multiple converging mechanisms, of which ECS dysregulation is one. The ECS role in sleep architecture is documented: CB1 activity in hypothalamic sleep-regulating circuits supports slow-wave sleep and REM. Reduced ECS tone reduces this support. Simultaneously, the elevated cortisol patterns associated with the perimenopausal HPA axis dysregulation disrupt sleep through a separate but interacting pathway. Both mechanisms are operating simultaneously in many perimenopausal women, and both involve the ECS.

Mood instability and anxiety — the psychological symptom cluster that many women describe as the most disorienting aspect of perimenopause — map directly to the limbic ECS that estrogen normally supports. The prefrontal cortex and amygdala, where estrogen-dependent CB1 upregulation is most significant, are the regions most involved in emotional regulation and anxiety modulation. When estrogen withdraws its upregulatory support, these circuits lose a layer of regulatory capacity that affects not just the severity of emotional responses but their predictability — which is why mood instability rather than simply low mood or elevated anxiety is often the presenting experience.

Cognitive changes — the "brain fog" that many women report in perimenopause — involve hippocampal function, where estrogen-dependent CB1 expression is particularly well-documented. The hippocampus is central to working memory, cognitive flexibility, and new learning. When ECS support in hippocampal circuits is reduced alongside the direct estrogenic effects on hippocampal neuroplasticity, the result can be a compound cognitive impact that is real, measurable on testing, and not explained by sleep disruption alone.

The Cuttler 2024 Data — Relevance to Perimenopause

The Cuttler 2024 trial — the primary human evidence anchor for CBG's stress and HPA axis effects in this archive — enrolled a predominantly female participant population and found significant reductions in perceived stress, anxiety, and negative affect alongside biological markers of HPA axis modulation. The trial did not stratify results by menopausal status, so direct evidence for CBG efficacy specifically in perimenopausal women is not available from this data. What is available is a human trial showing CBG effects on the same symptom domains — stress, anxiety, negative affect, HPA axis activity — that perimenopause disrupts through the estrogen-ECS pathway.

This is a reasonable inference from intersecting mechanisms, not a clinical claim for perimenopause specifically. The research question — whether CBG or CBD preparations produce meaningful benefit for perimenopausal symptoms through ECS support — has not been answered by a dedicated perimenopausal trial. It is a question that the mechanistic evidence strongly motivates, and one that the field is beginning to address.

What the Existing Research Does and Does Not Support

A 2020 observational study by Dahlgren and colleagues surveyed women using cannabis products for menopausal symptom management and found that the most commonly reported benefits were improved sleep, reduced anxiety, and reduced pain — the same symptom domains that ECS disruption in perimenopause would predict. This is observational data from a self-selected population using mixed cannabis products, not a controlled trial of specific cannabinoid preparations in perimenopause — the limitations are significant. But the pattern of reported benefits is consistent with the mechanistic framework, and consistent observational patterns across independent samples generate hypotheses worth pursuing.

CBD's specific relevance to perimenopause includes its FAAH inhibition — directly addressing the increased FAAH activity that estrogen withdrawal produces — and its 5-HT1A agonism, which supports serotonergic signalling that estrogen normally upregulates and perimenopause disrupts. CBG's alpha-2 adrenoceptor agonism and HPA axis modulation address the heightened stress reactivity and cortisol dysregulation that compound perimenopausal ECS disruption. Both compounds have mechanistically coherent rationales for perimenopausal application. Neither has dedicated perimenopausal clinical trial evidence.